-- China National Accord Medicines' (SHE:000028, SHE:200028) attributable profit fell 12% in the three months ended March 31 to 287.5 million yuan from 328 million yuan a year prior, according to a Tuesday Hong Kong bourse filing by parent Sinopharm (HKG:1099).
The drug company's basic EPS slid to 0.52 yuan from 0.59 yuan in the year-ago period.
Revenue inched down 2.6% year over year to 17.8 billion yuan from 18.3 billion yuan previously.